AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chemours expects double-digit growth for Opteon and $5.7B-$5.8B in sales for 2025, with the TSS segment outperforming expectations. Despite macroeconomic weakness affecting some sectors, the company exceeded adjusted EBITDA expectations due to diligent execution and operational improvements.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet